Survival and recurrence rates following SBRT or surgery in medically operable Stage I NSCLC

被引:1
|
作者
Snider, Michael [1 ]
Salama, Joseph K. [1 ,2 ]
Boyer, Matthew [1 ,2 ]
机构
[1] Duke Univ, Sch Med, Dept Radiat Oncol, Durham, NC USA
[2] Durham VA Hlth Care Syst, Radiat Oncol Clin Serv, Durham, NC USA
关键词
Early stage NSCLC; Surgical candidates; SBRT; Lobectomy; Sub-lobar resection; CELL LUNG-CANCER; STEREOTACTIC ABLATIVE RADIOTHERAPY;
D O I
10.1016/j.lungcan.2024.107962
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Surgery is the standard of care for early-stage non-small cell lung cancer (NSCLC), with SBRT reserved for patients who are not surgical candidates. We hypothesized overall survival (OS), lung cancer-specific survival (LCSS), progression free survival (PFS), and recurrence rates following SBRT or surgery in medically operable patients with Stage I NSCLC from the Veterans' Health Care System (VAHS) would be equivalent. Materials and methods: Medically operable patients diagnosed with Stage I NSCLC between 2000-2020 from the VAHS, determined by an FEV1 or DLCO > 60 % of predicted and Charlson comorbidity index (CCI) of 0 or 1, treated with SBRT or surgery were identified. SBRT patients were propensity score matched in a 1:1:1 ratio to those undergoing resection (SBRT:lobectomy:sub-lobar resection). OS, LCSS, and PFS and site of recurrence were determined. Results: 103 patients were included in each cohort. With a median follow-up of 7.9 years 5-year OS for all patients was 51 % (95 % CI 46-57 %). After propensity score matching, OS (HR 2.08, 1.59), LCSS (HR 2.28, 1.97), and PFS (1.97, 1.45) were significantly worse with SBRT compared to either lobectomy or sub-lobar resection, respectively, (p < 0.05 for each comparison). Regional recurrence was significantly higher following SBRT (15.5 % vs 6.8 % or 4.9 %; p < 0.05), but there was no significant difference in local (28.2 % vs 21.4 % or 21.4 %; p > 0.05) or distant recurrence (10.7 % vs 9.7 % or 13.6 %; p > 0.05) when compared to lobectomy or sub-lobar resection, respectively. Conclusion: In medically operable patients, OS, LCSS, and PFS following either lobectomy or sub-lobar resection were superior to that for SBRT for Stage I NSCLC, likely due in part to higher regional recurrence following SBRT. This suggests that pulmonary function test results and CCI alone are insufficient to define a cohort of medically operable patients suited for SBRT. These data support strategies to overcome regional recurrences seen with SBRT.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Long-term result of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT
    Lindberg, K.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S98 - S99
  • [32] Identifying Predictors of Distant Relapse Following SBRT for Stage I NSCLC: Is There a Role for Systemic Therapy?
    Wong, J. K.
    DeMora, L.
    Shaikh, T.
    Borghaei, H.
    Meyer, J. E.
    Hallman, M. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E502 - E503
  • [33] Risk Factors Associated with Recurrence Following Curative Therapy for Stage I NSCLC
    Butts, E.
    Gococo-Benore, D.
    Pai, T.
    Moustafa, M. Alhaj
    Heng, F.
    Chen, R.
    Manochakian, R.
    Lou, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S283 - S283
  • [34] Local recurrence rates after operable rectal cancer surgery
    Khera, G.
    Nadler, R. E.
    Brown, D.
    Hignett, S.
    Makin, C.
    BRITISH JOURNAL OF SURGERY, 2012, 99 : 102 - 103
  • [35] Stage I NSCLC: Risk Factors for Recurrence
    Shostak, E.
    Liberman, R.
    Riker, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [36] SBRT FOR INOPERABLE STAGE I AND II NSCLC: EVALUATION OF LOCAL CONTROL, SURVIVAL, PROGRESSION MODALITY AND TOXICITY
    Casamassima, F.
    Menichelli, C.
    Bonucci, I.
    Masciullo, S.
    Doro, R.
    Masi, L.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S354 - S354
  • [37] Robotic SBRT with Fiducial Tracking for Inoperable Peripheral Stage I NSCLC: Mature Survival and Toxicity Outcomes
    Aghdam, Nima
    Bhasin, Richa
    Malik, Ryan
    Kataria, Shaan
    Suy, Simeng
    Collins, Sean
    Chang, Thomas
    Benovac, Filip
    Anderson, Eric
    Collins, Brian
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S679 - S679
  • [38] Hypofractionated stereotactic body radiotherapy (SBRT) for medically unresectable stage I non-small cell lung cancer (NSCLC)
    Nambiar, A. P.
    Ajlouni, M.
    Jin, J.
    Ryu, S.
    Kim, J. H.
    Movsas, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S484 - S484
  • [39] Surgery for stage I NSCLC in Japan
    Tsuchiya, Ryosuke
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (07) : S113 - S114
  • [40] Should All Medically Inoperable Patients with Early-Stage NSCLC Need SBRT Treatment?
    Biswas, T.
    Vempati, P.
    Efird, J. T.
    Zheng, Y.
    Podder, T. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E6 - E6